Keytruda infusion how often?

Typical Infusion Schedule for Keytruda

Keytruda (pembrolizumab) is administered via intravenous (IV) infusion in a healthcare setting. The recommended dose and schedule for Keytruda vary depending on the specific indication and the patient's response to treatment.

Cancer Treatment Schedule

For cancer treatment, Keytruda is typically infused over 30 minutes every 3 weeks (21-day cycle). This schedule is based on the FDA-approved dosing regimen for various types of cancer, including melanoma, non-small cell lung cancer, and head and neck cancer [1]. However, the infusion schedule may be adjusted based on the patient's individual needs and response to treatment.

Dose Reduction and Delay

If a patient experiences a severe side effect or toxicity, the Keytruda dose may be reduced or delayed. Patients who have received a lower dose of Keytruda or have had their treatment delayed may experience reduced efficacy or may not respond well to the treatment [2].

Maintenance Therapy

In some cases, Keytruda is used as maintenance therapy after initial treatment with other therapies. For patients with head and neck cancer, maintenance therapy with Keytruda can be administered every 6 weeks (42-day cycle) [3].

Patient Concerns

Patients on Keytruda treatment should discuss any concerns or questions about the infusion schedule with their healthcare provider. It's essential to follow the recommended treatment schedule to ensure optimal efficacy and minimize the risk of adverse events.

Sources

[1] Keytruda (pembrolizumab) Prescribing Information. (2022). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/125514s018lbl.pdf

[2] FDA. (2022). Keytruda (pembrolizumab). Retrieved from https://www.fda.gov/drugs/information-drug-class/keytruda-pembrolizumab

[3] Keytruda (pembrolizumab) Prescribing Information. (2022). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/125514s018lbl.pdf